Curated News
By: NewsRamp Editorial Staff
September 15, 2026
Quantum BioPharma to Present at ArcStone-Kingswood Summit, Eyes Phase 2 MS Trial
TLDR
- Quantum BioPharma presents at the ArcStone-Kingswood Growth Summit, showcasing its FDA-approved Phase 2 multiple sclerosis program to gain a competitive edge.
- Quantum BioPharma's FDA IND approval for Lucid-MS enables Phase 2 trials in progressive MS, targeting myelin degradation through its patented compound.
- Quantum BioPharma advances Lucid-MS for multiple sclerosis, potentially reversing myelin damage and improving lives for those with neurodegenerative disorders.
- Quantum BioPharma will present at the ArcStone-Kingswood Growth Summit, highlighting its FDA-approved multiple sclerosis trial and innovative biotech solutions.
Impact - Why it Matters
This news matters because Quantum BioPharma is advancing a first-in-class multiple sclerosis treatment, Lucid-MS, into Phase 2 trials after FDA clearance. With no approved therapies for progressive MS, a successful outcome could transform treatment paradigms and offer new hope to patients. For investors, the presentation at the ArcStone-Kingswood Growth Summit provides a window into Quantum’s strategy and upcoming catalysts, while the UNBUZZD™ royalty agreement adds a potential revenue stream. As the biotech sector continues to innovate, Quantum’s progress underscores the importance of supporting research into challenging neurodegenerative and metabolic disorders, which affect millions worldwide.
Summary
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, will present at the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto. Co-founder and Executive Co-chairman Anthony Durkacz will highlight recent milestones and the company’s future growth strategy. A key recent milestone is the U.S. Food and Drug Administration’s approval of its Investigational New Drug application for Lucid-MS, clearing the way for Phase 2 trials in patients with progressive multiple sclerosis. This marks a significant step for Quantum’s lead compound, which is a patented new chemical entity shown preclinically to prevent and reverse myelin degradation.
Quantum’s pipeline also includes UNBUZZD™, an alcohol misuse treatment invented by the company and spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026. The agreement provides Quantum with a 7% royalty on sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses. For more details, see the full press release at https://ibn.fm/L1aXe, and the latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The original release can be viewed on newmediawire.com.
As a forward-looking company, Quantum operates in a high-risk, high-reward sector where clinical trial outcomes and regulatory decisions heavily influence valuation. The upcoming presentation at the ArcStone-Kingswood Growth Summit offers investors and partners insight into Quantum’s strategic direction and near-term catalysts, particularly the advancement of Lucid-MS into Phase 2. With no approved treatments for progressive MS, Quantum’s program could address a major unmet need if successful. Additionally, the UNBUZZD™ royalty stream provides a potential non-dilutive revenue source, further strengthening the company’s financial position as it pursues its core biopharma initiatives.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma to Present at ArcStone-Kingswood Summit, Eyes Phase 2 MS Trial
